glp 1 proteinuria Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria Glucagon-like Peptide-1 Receptor Agonists and

* Additional details on other secondary outcomes other than the change in body weight can be found at as NCT03954834 (SURPASS-1), NCT03987919 (SURPASS-2), NCT03882970 (SURPASS-3), NCT03730662 (SURPASS-4), NCT04039503 (SURPASS-5), NCT04537923 (SURPASS-6), NCT04255433 (SURPASS-CVOT), NCT03861052(SURPASS J-mono), NCT04093752 (SURPASS-AP-Combo), and NCT04184622 (SURMOUNT-1)

Greco V et al

4h, i, Table 1)

Better knowledge of how DPP-4 interacts with these cytokines may provide novel therapeutic strategies for inflammatory diseases [11]

It participates in the Keap1/Nrf2/ARE biological pathway the primary mechanism by which sulforaphane exerts its beneficial effects